公开(公告)号：US10323027B2

公开(公告)日：2019-06-18

申请号：US15735418

申请日：2016-06-23

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro Sugimoto ,  Shinkichi Suzuki ,  Hiroki Sakamoto ,  Masami Yamada ,  Minoru Nakamura ,  Makoto Kamata ,  Kenichiro Shimokawa ,  Masataka Murakami ,  Jinichi Yonemori ,  Takuto Kojima

IPC: C07D413/14 ,  C07D413/04 ,  C07D413/06 ,  C07D413/10 ,  C07D417/06 ,  C07D471/04 ,  C07D265/22 ,  C07D491/107 ,  C07F7/02 ,  A61P25/28 ,  C07D417/10 ,  C07F7/08

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

公开(公告)号：US10131653B2

公开(公告)日：2018-11-20

申请号：US15568644

申请日：2016-04-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Taku Kamei ,  Yasuyoshi Arikawa ,  Tomohiro Ohashi ,  Toshihiro Imaeda ,  Ikuo Fujimori ,  Takashi Miki ,  Jinichi Yonemori ,  Yuya Oguro ,  Takahiro Sugimoto ,  Masaki Seto ,  Goushi Nishida ,  Makoto Kamata ,  Hiroshi Imoto

IPC: C07D413/14 ,  C07D409/14 ,  C07D413/04 ,  C07D417/14 ,  A61P25/20 ,  A61P25/28 ,  A61P25/30 ,  A61P25/22 ,  A61P25/18 ,  A61P25/24 ,  A61K31/553

Abstract: The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.